Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017;102(10):1683–90.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
Miano M, Dufour C. The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015;101(6):527–35.
Stalder MP, Rovo A, Halter J, et al. Aplastic anemia and concomitant autoimmune diseases. Ann Hematol. 2009;88(7):659–65.
Singh NP, Prakash A, Garg D, et al. Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine. Rheumatol Int. 2004;24(1):40–2.
Matsumoto N, Kagawa H, Ichiyoshi H, et al. Aplastic anemia complicating Sjogren's syndrome. Intern Med. 1997;36(5):371–4.
Pamuk GE, Pamuk ON, Umit EG, Puyan FO, Ozturk E, Demir M. Antineutrophil cytoplasmic antibody associated vasculitis in one patient with severe aplastic anemia: description of the first case. Leuk Res. 2009;33(8):e95–7.
McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162–72.
Zhang M, Guan N, Zhu P, et al. Recurrent anti-GBM disease with T-cell large granular lymphocytic leukemia: a case report. Medicine. 2019;98(31):e16649.
Gu Q-H, Jia X-Y, Hu S-Y, et al. The clinical and immunologic features of patients with combined anti-GBM disease and castleman disease. Am J Kidney Dis. 2018;71(6):904–8.
Basnet A, Cholankeril MR. Hemophagocytic lymphohistiocytosis in a patient with Goodpasture's syndrome: a rare clinical association. Am J Case Rep. 2014;15:431–6.
Wang J, Jelcic I, Mühlenbruch L, et al. HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. Cell. 2020;183(5):1264–1281.e20.
Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1∗1501 and DRB1∗1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007;35(1):13–20.
Kitagawa W, Imai H, Komatsuda A, et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant. 2008;23(10):3126–9.
Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, et al. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.
Seiki Y, Sasaki Y, Hosokawa K, et al. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica. 2013;98(6):901–7.
Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96(6):2049–54.
Dunckley H, Chapman JR, Burke J, et al. HLA-DR and -DQ genotyping in anti-GBM disease. Dis Markers. 1991;9(5):249–56.
Huey B, McCormick K, Capper J, et al. Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization. Kidney Int. 1993;44(2):307–12.
Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int. 1997;51(1):222–9.
Kapusttn SI, Popova TI, Lyschov AA, Togo AV, Abdulkadyrov KM, Blinov MN. HLA-DR2 frequency increase in severe aplastic anemia patients is mainly attributed to the prevalence of DR15 subtype. Pathol Oncol Res. 1997;3(2):106–8.
Saunthararajah Y, Nakamura R, Nam J-M, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570–4.
Qahtani SAA. Drug-induced megaloblastic, aplastic, and hemolytic anemias: current concepts of pathophysiology and treatment. Int J Clin Exp Med. 2018;11(6):5501–12.
Yu Z, Hu J, Hu Y. Neutropenia and thrombocytopenia induced by proton pump inhibitors: a case report. Drug Saf Case Rep. 2018;5(1):28.
Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–19.
Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl. 1996;60:23–30.
Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
Ilhan O, Beksac M, Koc H, et al. HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood. 1995;86(5):2055.
Morishita Y, Matsukawa Y, Kura Y, et al. Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. J Int Med Res. 1997;25(4):219–23.